

## Blinded phase: Optic and Ocular: Number of participants with resolution of macular oedema

Two of the three participants who had resolution of macular oedema were eligible in both eyes. Since both these participants experienced resolution in both eyes there was no difference in results when considering the assumption that the resolution must occur in both eligible eyes.

**Table 1: Resolution of macular oedema**

Treatment	Number randomised	Number who had macular oedema at baseline	Number who did not have macular oedema at baseline, but developed it at some other point during the study	Number who had macular oedema at baseline or developed it at some point during the study	Number with resolution of macular oedema, N (%)
Placebo	30	1 (3.33%)	1 (3.33%)	2 (6.67%)	0 (0%)
Adalimumab	60	4 (6.67%)	0 (0%)	4* (6.67%)	3** (75.00%)
<b>Total</b>	<b>90</b>	<b>5 (5.56%)</b>	<b>1(1.11%)</b>	<b>6 (6.67%)</b>	<b>3 (33.33%)</b>
		Relative risk of resolution of macular oedema (either from baseline or that which had developed) (95% CI)		Fisher's Exact Test P-value	
		5.00 (0.34, 74.52))		0.40	